A 4‐site, single‐visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients.
We previously demonstrated that 4&#x2010;site, intradermal, single&#x2010;visit rabies booster vaccination provides immunogenicity greater than that provided by the standard 2&#x2010;booster, 2&#x2010;visit regimen. The regimen has been routinely used in 5116 patients since 1998 without any treatment failure. It is not only effective but also saves vaccine costs and transportation expenses and improves compliance.
Shantavasinkul
Prapimporn
P
Queen Saovabha Memorial Institute, Thai Red Cross Society, World Health Organization Collaborating Center for Research in Rabies Pathogenesis and Treatment, Bangkok, Thailand. sprapimporn@gmail.com
Tantawichien
Terapong
T
Jaijaroensup
Wipaporn
W
Lertjarutorn
Samran
S
Banjongkasaena
Ampai
A
Wilde
Henry
H
Sitprija
Visith
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001733:Bites and Stings / Q000150:complications; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011818:Rabies / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D012189:Retrospective Studies; D013785:Thailand; D016896:Treatment Outcome; D055815:Young Adult
D011819:Rabies Vaccines